Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Ashida, Reiko ^a   Nakata, Bunzo ^a   Shigekawa, Minoru ^b   Mizuno, Nobumasa ^b   Sawaki, Akira ^b   Hirakawa, Kosei ^a   Arakawa, Tetsuo ^a   Yamao, Kenji ^b  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; GEMCITABINE; MESSENGER RNA; NUCLEOSIDE TRANSPORTER; RIBONUCLEOTIDE REDUCTASE; TUMOR MARKER; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CLINICAL ARTICLE; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PATIENT CODING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA EXTRACTION; ADENOCARCINOMA; DNA MICROARRAY; ECHOGRAPHY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PANCREAS TUMOR; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY, FINE-NEEDLE; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 68149107766     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-83     Document Type: Article

References (26)

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff, J Clin Oncol 1997 15 2403 2413 9196156
2. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. J Spratlin R Sangha D Glubrecht L Dabbagh JD Young C Dumontet C Cass R Lai JR Mackey, Clin Cancer Res 2004 10 6956 6961 10.1158/1078-0432.CCR- 04-0224 15501974 (Pubitemid 39383046)
3. Transcription analysis of human equilibrative nucleoside transpoter-1 predicts survival in pancreas cancer patients treated with gemcitabine. E Giovannetti M Del Tacca V Mey N Funel S Nannizzi S Ricci C Orlandini U Boggi D Campani M Del Chiaro M Iannopollo G Bevilacqua F Mosca R Danesi, Cancer Res 2006 66 3928 3935 10.1158/0008-5472.CAN-05-4203 16585222
4. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. JR Mackey SY Yao KM Smith E Karpinski SA Baldwin CE Cass JD Young, J Natl Cancer Inst 1999 91 1876 1881 10.1093/jnci/91.21.1876 10547395
5. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. JR Kroep WJP Loves CL van der Wilt E Alvarez I Talianidis E Boven BJ Braakhuis CJ van Groeningen HM Pinedo GJ Peters, Mol Cancer Ther 2002 1 371 376 12477049
6. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. V Sebastiani F Ricci B Rubio-Viquiera P Kulesza CJ Yeo M Hidalgo A Klein D Laheru CA Iacobuzio-Donahue, Clin Cancer Res 2006 12 2492 2497 10.1158/1078-0432.CCR-05-2655 16638857
7. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. M Tada Y Komatsu T Kawabe N Sasahira H Isayama N Toda Y Shiratori M Omata, Am J Gastroenterol 2002 97 2263 2270 10.1111/j.1572-0241.2002.05980.x 12358243
8. Endoscopic ultrasound fine needle aspiration DNA analysis to differentiate malignant and benign pancreatic masses. A Khalid L Nodit M Zahid K Bauer D Brody SD Finkelstein KM McGrath, Am J Gastroenterol 2006 101 2493 2500 17029619
9. Endosonograpy-guided real-time fine-needle aspiration biopsy. MJ Wiersema ML Kochman HM Cramer LC Tao LM Wiersema, Gastrointest Endosc 1994 40 700 707 7859968
10. An evaluation of linear RNA amplification in cDNA microarray gene expression analysis. B Zhu F Xu Y Bana, Mol Genet Metab 2006 87 71 79 10.1016/j.ymgme.2005.08.007 16214384 (Pubitemid 43003770)
11. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. K Takahashi K Yamao K Okubo A Sawaki N Mizuno R Ashida T Koshikawa Y Ueyama K Kasugai S Hase S Kakumu, Gastrointest Endosc 2005 61 76 79 10.1016/S0016-5107(04)02224-2 15672060 (Pubitemid 40169815)
12. Specialized DNA arrays for the differentiation of pancreatic tumors. M Buchholz HA Kestler A Bauer W Bock B Rau G Leder W Kratzer M Bommer A Scarpa MK Schilling G Adler JD Hoheisel TM Gress, Clin Cancer Res 2005 11 8048 8054 10.1158/1078-0432.CCR-05-1274 16299235 (Pubitemid 41698747)
13. The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analysis. L Assersohn L Gangi Y Zhao M Dowsett R Simon TJ Powles ET Liu, Clin Cancer Res 2002 8 794 801 11895911
14. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. L Pusztai M Ayers J Stec E Clark K Hess D Stivers A Damokosh N Sneige TA Buchholz FJ Esteva B Arun M Cristofanilli D Booser M Rosales V Valero C Adams GN Hortobagyi WF Symmans, Clin Cancer Res 2003 9 2406 2415 12855612
15. Feasibility of using low-volume tissue samples for gene expression profiling of advanced non-small cell lung cancers. EH Lim A Aggarwal T Agasthian PS Wong C Tan E Sim L Tan PS Goh SC Wang KL Khoo A Mukherjee SM Khoo G Chua B Nilsson KH Lee P Tan, Clin Cancer Res 2003 9 5980 5987 14676123
16. High-fidelity mRNA amplification for gene profiling. E Wang LD Miller GA Ohnmacht ET Liu FM Marincola, Nat Biotechnol. 2000 18 4 457 459 10.1038/74546 10748532 (Pubitemid 30217539)
17. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. AM Storniolo NH Enas CA Brown M Voi ML Rothenberg R Schilsky, Cancer 1999 85 1261 1268 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T 10189130
18. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. JD Berlin P Catalano JP Thomas JW Kugler DG Haller AB Benson 3rd, J Clin Oncol 2002 20 3270 3275 10.1200/JCO.2002.11.149 12149301 (Pubitemid 34831525)
19. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. AH Ko J Hwang AP Venook JL Abbruzzese EK Bergsland MA Tempero, Br J Cancer 2005 93 195 199 10.1038/sj.bjc.6602687 15999098 (Pubitemid 41133205)
20. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. H Achiwa T Oguri S Sato H Maeda T Niimi R Ueda, Cancer Sci 2004 95 753 757 10.1111/j.1349-7006.2004.tb03257.x 15471562 (Pubitemid 39335096)
21. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. R Mori T Ishikawa Y Ichikawa K Taniguchi R Matsuyama M Ueda Y Fujii I Endo S Togo PV Danenberg H Shimada, Oncol Rep 2007 17 1201 1205 17390066
22. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Y Nakano S Tanno K Koizumi T Nishikawa K Nakamura M Minoguchi T Izawa Y Mizukami T Okumura Y Kohgo, Br J Cancer 2007 96 457 463 10.1038/sj.bjc.6603559 17224927 (Pubitemid 46215217)
23. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. JD Davidson L Ma M Flagella S Geeganage LM Gelbert CA Slapak, Cancer Res 2004 64 3761 3766 10.1158/0008-5472.CAN-03-3363 15172981 (Pubitemid 38697284)
24. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. AM Bergman PP Eijk VW Ruiz van Haperen K Smid G Veerman I Hubeek P van den Ijssel B Ylstra GJ Peters, Cancer Res 2005 65 9510 9516 10.1158/0008-5472.CAN-05-0989 16230416 (Pubitemid 41508021)
25. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. S Nakahira S Nakamori M Tsujie Y Takahashi J Okami S Yoshioka M Yamasaki S Marubashi I Takemasa A Miyamoto Y Takeda H Nagano K Dono K Umeshita M Sakon M Monden, Int J Cancer. 2006 120 6 1355 1363 10.1002/ijc.22390
26. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinoma. T Itoi A Sofuni N Fukushima F Itokawa T Tsuchiya T Kurihara F Moriyasu A Tsuchida K Kasuya, J Gastroenterol 2007 42 389 394 10.1007/s00535-007-2017-0 17530364 (Pubitemid 47097256)